This piece by a Web Editor Patricia Daddona originally appeared in The Hartford Business Journal January 12, 2017.
Protein Sciences Corp., a vaccine development company, said good safety results included inducing strong neutralizing antibodies against the Zika virus. The product is expected to advance into human clinical trials in April, the company said.
The Institute of Technology in Immunobiologicals of the Oswaldo Cruz Foundation (Bio-Manguinhos/Fiocruz) also has joined the multinational consortium that is sponsoring development of the Zika vaccine, the company said.
The vaccine candidate is composed of purified protein that matches a protein found on the outer surface of the Zika virus (the E protein) and was created using Protein Sciences’ proprietary BEVS technology.
“Zika remains a substantial threat in several parts of the world,” said Manon Cox, company President and CEO. “Our new data and Fiocruz, through Bio-Manguinhos´ participation in our consortium, bring us another step closer to realizing a vaccine that will protect against this deadly virus.”